Comparative efficacy of CDK4/6 inhibitors palbociclib, ribociclib, and abemaciclib in HR+/HER2- advanced breast cancer
American Journal of Cancer Research · 2026 · 16 (5) · 1805-1816
DOI: 10.62347/hykp5700 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Cancer Research, 2026. Verfasst von Bo Hou und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, The First People's Hospital of Chun'an County Chun'an 311700, Zhejiang, China. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology, The First People's Hospital of Chun'an County Chun'an 311700, Zhejiang, China.
- Department of Pharmacy, Ganzhou Fifth People's Hospital Ganzhou 341000, Jiangxi, China.
Zitieren
APA
Hou, B., & Zhang, Y. (2026). Comparative efficacy of CDK4/6 inhibitors palbociclib, ribociclib, and abemaciclib in HR+/HER2- advanced breast cancer. American Journal of Cancer Research, 16(5), 1805-1816. https://doi.org/10.62347/hykp5700
Vancouver
Hou B, Zhang Y. Comparative efficacy of CDK4/6 inhibitors palbociclib, ribociclib, and abemaciclib in HR+/HER2- advanced breast cancer. American Journal of Cancer Research. 2026;16(5):1805-1816. doi:10.62347/hykp5700
BibTeX
@article{Hou2026,
author = {Hou, Bo and Zhang, Yu},
title = {Comparative efficacy of CDK4/6 inhibitors palbociclib, ribociclib, and abemaciclib in HR+/HER2- advanced breast cancer},
journal = {American Journal of Cancer Research},
year = {2026},
volume = {16},
number = {5},
pages = {1805--1816},
doi = {10.62347/hykp5700}
}
EUVIMED